Victorian Clinical Genetics Services, Murdoch Childrens Research Institute and University of Melbourne Australia
Ravi Savarirayan is consultant clinical geneticist at Victorian Clinical Genetics Services, Professorial fellow at the University of Melbourne, and Research Group leader (Musculoskeletal disease) at Murdoch Children’s Research Institute, Victoria, Australia.
Professor Savarirayan received his MBBS from the University of Adelaide, Australia in 1990 and became a Fellow of the Royal Australasian College of Physicians in 1997. He was certified as a specialist in Clinical Genetics by the Human Genetics Society of Australasia in 1998, and was awarded his Doctorate of Medicine from the University of Melbourne in 2004, for his thesis “Clinical and molecular studies in the Osteochondrodysplasias.” He was the youngest recipient of the Fulbright Professional Award for Australia in 1998, and took his fellowship up at University of California, Los Angeles (UCLA).
Professor Savarirayan is a founding member of the Skeletal Dysplasia Management Consortium and is the current Chair of the Advanced Training Committee in Clinical Genetics, Royal Australasian College of Physicians. He was the first Australian elected President of the International Skeletal Dysplasia Society, and has been invited to give plenary talks at major scientific conferences in North and South America, Asia, Europe, and Australasia.
Professor Savarirayan’s primary research focus is on inherited disorders of the skeleton causing short stature, arthritis and osteoporosis. He has published over 160 peer-reviewed articles, collaborating with researchers from over 40 countries. He serves on the editorial boards several prestigious journals, including Human Mutation, European Journal of Human Genetics, American Journal of Medical Genetics, and Journal of Medical Genetics.
His current clinical and research activities focus on the translation of genomic data into tangible and meaningful outcomes for individuals, families, and health care systems, and advocating for equal access and uptake of new genetic technology and therapies. He was recently named one of the “Brilliant Minds” of the Murdoch Children’s Research Institute over the past 30 years.
